Callan JMB Inc. has released its financial results for the second quarter of 2025. The company reported revenues of $1.7 million for the three-month period and $3.1 million for the six months ended June 30, 2025, marking a year-over-year decrease attributed to a decline in demand for emergency preparedness services by certain states and local governments. The cost of revenues for the corresponding three-month and six-month periods were $1.0 million and $1.9 million, respectively, reflecting a decrease in line with the revenue decline. Gross profit amounted to $0.6 million for the three months and $1.3 million for the six months ended June 30, 2025. The company reported a loss from operations of $1.4 million for the three months and $2.6 million for the six months ended June 30, 2025. SG&A expenses increased year-over-year to $2.0 million for the quarter and $3.9 million for the half-year, primarily due to higher consulting, professional fees, marketing expenses, and staffing costs as the company transitions to being a public entity. In terms of business updates, Callan JMB formed a strategic partnership with Revival Health Inc. to develop integrated supply chain services for health, wellness, and longevity products. The company also launched a subsidiary in India, establishing a temperature-controlled warehouse for pharmaceuticals, and extended a long-term contract with the City of Chicago, securing increased funding. Additionally, Callan JMB supported measles outbreak response efforts in Texas and New Mexico by redistributing MMR II vaccines. The company ended the quarter with $4.2 million in cash and cash equivalents and entered into an equity line of credit agreement to sell up to $25 million of shares of its common stock.